{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:18:33Z","timestamp":1791065913750,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.3816\/clml.2010.n.086","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T11:00:01Z","timestamp":1299063601000},"page":"414-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["A Decade of Progress in Lymphoma: Advances and Continuing Challenges"],"prefix":"10.3816","volume":"10","author":[{"given":"Christopher R.","family":"Flowers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.086_bib1","article-title":"Cancer Statistics. 2010","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLML.2010.n.086_bib2","series-title":"Manual of tumor nomenclature and coding","year":"1968"},{"key":"10.3816\/CLML.2010.n.086_bib3","series-title":"ICD-O International Classification of Diseases for Oncology","year":"1976"},{"key":"10.3816\/CLML.2010.n.086_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib5","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001"},{"key":"10.3816\/CLML.2010.n.086_bib6","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"10.3816\/CLML.2010.n.086_bib8","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib9","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.3816\/CLML.2010.n.086_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematology (Am Soc Hematol Educ Program"},{"key":"10.3816\/CLML.2010.n.086_bib11","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.3816\/CLML.2010.n.086_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","article-title":"Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component","volume":"165","author":"Katzenberger","year":"2004","journal-title":"Am J Pathol"},{"key":"10.3816\/CLML.2010.n.086_bib13","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-010-0602-0","article-title":"Pathogenesis of diffuse large B cell lymphoma","author":"Chan","year":"2010","journal-title":"Int J Hematol"},{"key":"10.3816\/CLML.2010.n.086_bib15","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1182\/blood-2008-02-137372","article-title":"Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP","volume":"112","author":"Rimsza","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib17","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.086_bib18","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1084\/jem.20061292","article-title":"Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis","volume":"203","author":"Roulland","year":"2006","journal-title":"J Exp Med"},{"key":"10.3816\/CLML.2010.n.086_bib19","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.2008.21.2704","article-title":"Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia","volume":"27","author":"Shanafelt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2006.01.045","article-title":"Strategies to eliminate cancer stem cells: clinical implications","volume":"42","author":"Huff","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLML.2010.n.086_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","article-title":"CD20-targeted therapy: the next generation of antibodies","volume":"47","author":"van Meerten","year":"2010","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.086_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.seminhematol.2010.01.008","article-title":"Rituximab in high-grade lymphoma","volume":"47","author":"Zwick","year":"2010","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.086_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.seminhematol.2010.01.003","article-title":"Rituximab in indolent lymphomas","volume":"47","author":"Sousou","year":"2010","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.086_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3816\/CLM.2007.n.034","article-title":"Maintenance therapy in lymphoma","volume":"7","author":"Mihelic","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.086_bib25","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib26","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib27","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib29","first-page":"223A","article-title":"Mabthera (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large-B-cell lymphoma (DLCL): Interim results of a randomized GELA trial","volume":"96","author":"Coiffier","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.086_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.086_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib34","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib35","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib36","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib37","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib38","doi-asserted-by":"crossref","unstructured":"Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Presented at: the 51st ASH Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. Abstract 535.","DOI":"10.1182\/blood.V114.22.535.535"},{"key":"10.3816\/CLML.2010.n.086_bib39","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib40","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib41","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib42","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma","volume":"26","author":"Czuczman","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib43","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib44","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","article-title":"Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"key":"10.3816\/CLML.2010.n.086_bib45","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"14 suppl","key":"10.3816\/CLML.2010.n.086_bib47","article-title":"Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab \u2013 early stopping after the first interim analysis","volume":"22","author":"Pfreundschuh","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib48","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood.V97.5.1392","article-title":"Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin","volume":"97","author":"Ghetie","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib49","first-page":"1183","article-title":"Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis","volume":"2","author":"Jazirehi","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CLML.2010.n.086_bib50","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.086_bib51","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1158\/0008-5472.CAN-03-3500","article-title":"Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab","volume":"64","author":"Jazirehi","year":"2004","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.086_bib52","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"10.3816\/CLML.2010.n.086_bib53","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrc2717","article-title":"Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures","volume":"9","author":"Bendandi","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLML.2010.n.086_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2008.09.001","article-title":"Vaccines for lymphomas: idiotype vaccines and beyond","volume":"23","author":"Houot","year":"2009","journal-title":"Blood Rev"},{"key":"10.3816\/CLML.2010.n.086_bib55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib56","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4049\/jimmunol.138.4.1289","article-title":"Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein","volume":"138","author":"Kaminski","year":"1987","journal-title":"J Immunol"},{"key":"10.3816\/CLML.2010.n.086_bib57","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.93.20.10972","article-title":"Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte\/macrophage colony-stimulating factor primes mice for a protective T-cell response","volume":"93","author":"Kwak","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18 suppl","key":"10.3816\/CLML.2010.n.086_bib58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/jco.2009.27.18_suppl.2","article-title":"Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results","volume":"27","author":"Schuster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib59","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib60","doi-asserted-by":"crossref","unstructured":"Levy R, Robertson M, Ganjoo K, et al. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). Presented at: the AACR Annual Meeting, 2008. Abstract LB-204.","DOI":"10.1158\/1538-7445.AM2008-LB-204"},{"key":"10.3816\/CLML.2010.n.086_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/asheducation-2004.1.221","article-title":"Diffuse aggressive lymphoma","author":"Fisher","year":"2004","journal-title":"Hematology (Am Soc Hematol Educ Program"},{"key":"10.3816\/CLML.2010.n.086_bib62","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.086_bib63","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-102-5-596","article-title":"MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma","volume":"102","author":"Klimo","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLML.2010.n.086_bib64","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-104-6-757","article-title":"Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD","volume":"104","author":"Shipp","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLML.2010.n.086_bib65","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-104-3-338","article-title":"Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy","volume":"104","author":"Browne","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLML.2010.n.086_bib66","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib68","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/asheducation-2009.1.440","article-title":"State-of-the-art treatment of chronic lymphocytic leukemia","author":"Hallek","year":"2009","journal-title":"Hematology (Am Soc Hematol Educ Program"},{"key":"10.3816\/CLML.2010.n.086_bib69","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib70","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib72","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib73","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib74","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1998.16.1.70","article-title":"Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients","volume":"16","author":"Cheung","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives)","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib76","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib77","first-page":"427","article-title":"The effect of pre-irradiation dose intense CHOP on anthracycline resistance in localized nasal NK\/T-cell lymphoma","volume":"91","author":"Lee","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.086_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4717.4717","article-title":"A pilot study of alemtuzumab plus combination chemotherapy for newly diagnosed patients with peripheral T-cell lymphomas","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib79","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.086_bib80","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1053\/j.seminhematol.2010.01.012","article-title":"Enhancing existing approaches to peripheral T-cell lymphoma","volume":"47","author":"Foss","year":"2010","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.086_bib81","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib82","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib83","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1517\/14656566.2010.489552","article-title":"Pralatrexate: basic understanding and clinical development","volume":"11","author":"Zain","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.3816\/CLML.2010.n.086_bib84","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin's disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLML.2010.n.086_bib85","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.086_bib86","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.1987.5.1.27","article-title":"Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy","volume":"5","author":"Santoro","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.1994.12.2.279","volume":"12","author":"Somers","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib89","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib90","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1200\/JCO.2003.11.103","article-title":"High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy","volume":"21","author":"Federico","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib91","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1200\/JCO.2005.03.2151","article-title":"Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)","volume":"23","author":"Johnson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib92","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1200\/JCO.2005.02.907","article-title":"ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi","volume":"23","author":"Gobbi","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.086_bib93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/annonc\/13.S1.102","article-title":"ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial","volume":"13","author":"Chisesi","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin's lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib95","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4065\/81.3.419","article-title":"Management of Hodgkin lymphoma","volume":"81","author":"Ansell","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLML.2010.n.086_bib96","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib97","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib98","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8506","article-title":"Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups","author":"Gianni","year":"2008","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib99","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.086_bib100","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib101","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib102","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib103","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.086_bib104","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11899-010-0062-x","article-title":"Prognostic markers in peripheral T-cell lymphoma","volume":"5","author":"Piccaluga","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"10.3816\/CLML.2010.n.086_bib105","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.3816\/CLML.2010.n.086_bib106","first-page":"s62","article-title":"Who are the high-risk patients with Hodgkin's disease?","volume":"10","author":"Carde","year":"1996","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.086_bib107","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.1984.2.7.748","article-title":"The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease","volume":"2","author":"Cooper","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib108","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1053-4296(96)80012-9","article-title":"Prognostic factors in Hodgkin's disease","volume":"6","author":"Specht","year":"1996","journal-title":"Semin Radiat Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib109","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.1991.9.11.1983","article-title":"Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial","volume":"9","author":"Yelle","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib110","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.8-5-438","article-title":"PET scans in the staging of lymphoma: current status","volume":"8","author":"Friedberg","year":"2003","journal-title":"Oncologist"},{"key":"10.3816\/CLML.2010.n.086_bib111","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib112","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib113","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00130404-200509000-00011","article-title":"Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients","volume":"11","author":"Kahn","year":"2005","journal-title":"Cancer J"},{"key":"10.3816\/CLML.2010.n.086_bib114","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ijrobp.2006.07.1365","article-title":"Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: Implications for consolidation radiotherapy","volume":"66","author":"Kahn","year":"2006","journal-title":"Int J Rad Onc Biol Phys"},{"key":"10.3816\/CLML.2010.n.086_bib115","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib116","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2006.1.295","article-title":"Optimal use of prognostic factors in non-Hodgkin lymphoma","author":"Sehn","year":"2006","journal-title":"Hematology (Am Soc Hematol Educ Program"},{"key":"10.3816\/CLML.2010.n.086_bib117","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.currproblcancer.2010.04.007","article-title":"ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma","volume":"34","author":"Ng","year":"2010","journal-title":"Curr Probl Cancer"},{"key":"10.3816\/CLML.2010.n.086_bib118","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18) F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib119","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.108.057703","article-title":"Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy","volume":"50","author":"Itti","year":"2009","journal-title":"J Nucl Med"},{"key":"10.3816\/CLML.2010.n.086_bib120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdn671","article-title":"Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria","volume":"20","author":"Dupuis","year":"2009","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib121","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.086_bib122","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CLML.2010.n.056","article-title":"Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?","volume":"10","author":"Shenoy","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:30Z","timestamp":1761870210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S2152265011700428"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.086","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Decade of Progress in Lymphoma: Advances and Continuing Challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}